CN101953780A - Cefprozil solid preparation and preparation method thereof - Google Patents
Cefprozil solid preparation and preparation method thereof Download PDFInfo
- Publication number
- CN101953780A CN101953780A CN2010105181541A CN201010518154A CN101953780A CN 101953780 A CN101953780 A CN 101953780A CN 2010105181541 A CN2010105181541 A CN 2010105181541A CN 201010518154 A CN201010518154 A CN 201010518154A CN 101953780 A CN101953780 A CN 101953780A
- Authority
- CN
- China
- Prior art keywords
- cefprozil
- preparation
- reactant liquor
- silica gel
- solid preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Abstract
The invention relates to a cefprozil solid preparation and a preparation method thereof. The cefprozil solid preparation comprises cefprozil nanocapsules and medicinal auxiliary materials, wherein the nanocapsules are prepared from the cefprozil and a carrier material in the weight ratio of 6-11:1; and the carrier material is a xanthan gum-silk fibroin-aerosil composite, wherein the weight ratio of xanthan gum to silk fibroin to aerosol is 1.5-4.5:1. In the cefprozil solid preparation and the preparation method, the encapsulate rate is over 95 percent, the sudden release of medicaments is avoided, adverse reactions are reduced and the compliance of patients is improved.
Description
Technical field
The present invention relates to a kind of solid preparation and preparation method thereof, relate in particular to a kind of cefprozil solid preparation and preparation method thereof, belong to medical technical field.
Background technology
Cefprozil, chemical being called (6R, 7R)-the 3-acrylic-7-[(R)-2-amino-2-(4-hydroxy phenyl) acetylamino]-8-oxo-5-thia-1-azabicyclo [4.2.0] oct-2-ene-2-formic acid, structural formula is as follows:
This product is a second generation cephalosporin class antibiotic, the tool broad-spectrum antibacterial action.In vitro tests proves, this product is obvious to the effect of the staphylococcus aureus in the gram positive aerobic bacteria (comprise and produce the beta lactamase bacterial strain), streptococcus pneumoniae, micrococcus scarlatinae, to steadfast and persevering enterococcus, listerisa monocytogenes in mjme, staphylococcus epidermidis, staphylococcus saprophyticus, Warnei staphylococcus.Be used for following light, grade and moderate infection, 1. upper respiratory tract infection due to the sensitive organism: (1) micrococcus scarlatinae pharyngitis/tonsillitis; (2) streptococcus pneumoniae, bloodthirsty influenza bacterium (comprise and produce acyl ammonia enzyme bacterial strain in the B-) and moraxelle catarrhalis (comprise and produce acyl ammonia enzyme bacterial strain in the B-) property otitis media and acute sinusitis; 2. lower respiratory infection: the acute bronchitis secondary bacterial infection and the acute episode of chronic bronchitis that cause by streptococcus pneumoniae, bloodthirsty hemophilus influenza (comprise and produce acyl ammonia enzyme bacterial strain in the B-) and moraxelle catarrhalis (comprise and produce the interior acyl ammonia enzyme bacterial strain of B-); 3. skin and skin soft tissue: non-complex skin and skin soft-tissue infection that staphylococcus aureus (comprise and produce penicillium candidum strain) and micrococcus scarlatinae cause.
But in clinical practice, there is following untoward reaction in cefprozil:
Be mainly gastrointestinal reaction, comprise diarrhoea, feel sick, vomiting and stomachache etc.Also anaphylaxis can take place, common is erythra, urticaria.The child take place anaphylaxis the adult see that other untoward reaction comprise, liver and gall more: the AST(glutamic oxaloacetic transaminase, GOT) and the ALT(glutamate pyruvate transaminase) rising.Accidental alkaline phosphatase prunus mume (sieb.) sieb.et zucc. and bilirubin raise.Obstructive jaundice is rare; The central nervous system: dizzy, how moving, headache, psychentonia, insomnia.Accidental drowsiness.All these reactions all are reversibility; Blood system: leukopenia, eosinophilia; Kidney: serum urea nitrogen increases, and serum creatinine increases; Other: diaper dermatitis sample erythra and superinfection, genitals pruritus and vagina.In addition, the cefprozil life-time service can cause the undue growth of non-sensibility microorganism, changes normal intestinal flora, brings out superinfection, especially pseudomembranous colitis.Therefore suffer from gastroenteropathy, especially enteritis patient Ying Shen cefprozil.
In view of the wide clinical application of cefprozil, research and development cefprozil new formulation improves patient's compliance, reduces even stops untoward reaction, improves clinical safety in utilization, is the more urgent demand of cefprozil clinical practice.
Summary of the invention
Technical problem to be solved by this invention provides a kind of cefprozil solid preparation, and said preparation can significantly promote characteristics such as drug compliance, minimizing untoward reaction.In addition, the present invention also will provide the preparation method of said preparation.
Technical problem of the present invention solves with following technical scheme:
A kind of cefprozil solid preparation, contain cefprozil nano-microcapsule and pharmaceutic adjuvant in the said preparation, described nano-microcapsule is that 6～11:1 makes by cefprozil and carrier material with ratio of weight and number, described carrier material is xanthan gum-fibroin albumen-micropowder silica gel compositions, and wherein the ratio of weight and number of xanthan gum, fibroin albumen and micropowder silica gel is 1.5～4.5:1.
Above-mentioned cefprozil solid preparation, the ratio of weight and number of described xanthan gum, fibroin albumen and micropowder silica gel are 2.6:1.
Above-mentioned cefprozil solid preparation, described pharmaceutic adjuvant are diluent, disintegrating agent, adhesive, lubricant and fluidizer.
Above-mentioned cefprozil solid preparation, the dosage form of described preparation are tablet, capsule, dry suspension or granule.
A kind of method for preparing above-mentioned cefprozil solid preparation, it carries out as follows:
A. after ratio is mixed by weight with fibroin albumen with xanthan gum, stir fusion and insulation under 55～60 ℃ of conditions, slowly add micropowder silica gel while stirring, micropowder silica gel is uniformly dispersed, it is standby to get compositions;
B. be that the ratio of 3:1:8 makes microemulsion according to propoxylation methyl glucoside weight, isobutanol volume, ethyl acetate volume ratio, in emulsion, add cefprozil, place 40～60 ℃ of water-baths;
C. add a step resulting composition in microemulsion, be stirred to evenly, as reactant liquor, the pH value of regulating this reactant liquor with the NaOH solution of mass concentration 10% is 8.0～10.0, adds an amount of methanol with this solution, isothermal reaction 1～2 hour;
D. reactant liquor is cooled to 0 ℃, the glutaraldehyde that adds 0.08～0.125 times of reactant liquor volume continues to stir 30 minutes, slowly is warming up to 40～60 ℃ again, and adding glacial acetic acid to the value of pH is 2.0～4.0, obtains suspension;
E. treat after static that sedimentation is complete, the supernatant that inclines filters, and washes with water to no aldehyde flavor, drains, promptly.
The above-mentioned method for preparing the cefprozil solid preparation,
The temperature that stirs fusion and insulation among the described step a is 57 ℃;
Bath temperature is 50 ℃ among the described step b;
The pH value of reactant liquor is 9.0 among the described step c; Isothermal reaction 1.5 hours;
The glutaraldehyde consumption is 0.1 times of reactant liquor volume in the described steps d, slowly is warming up to 50 ℃, and the glacial acetic acid adjust pH is 3.0.
Cefprozil solid preparation provided by the present invention is a lapping with xanthan gum-fibroin albumen-micropowder silica gel compositions, usage ratio, melt temperature, insulation measure and various factors by investigating xanthan gum-fibroin albumen-micropowder silica gel is to the influence of preparation, determined preparation condition: the ratio of weight and number of xanthan gum, fibroin albumen and micropowder silica gel is 1.5～4.5:1:1, and 55～60 ℃ of melt temperatures also are incubated standby; The complex coacervation pH value is 8.0～10.0; The complex coacervation time is 1～2 hour; The amount of cross-linking agent is 0.08～0.125 times of a reactant liquor volume; Crosslinking time is 30 minutes.Especially the ratio of weight and number when xanthan gum, fibroin albumen and micropowder silica gel is 2.6:1:1, and 57 ℃ of melt temperatures also are incubated standby; The complex coacervation pH value is 9.0; The complex coacervation time is 1.5 hours; The amount of cross-linking agent is 0.1 times of a reactant liquor volume; When crosslinking time was 30 minutes, envelop rate reached more than 95% especially.Avoid medicine to dash forward and released, reduced untoward reaction, improved patient's compliance.
The specific embodiment
The invention will be further described below in conjunction with specific embodiment.
The preparation of the solid preparation of embodiment 1 cefprozil
(1) with after xanthan gum 15g, the fibroin albumen 10g mixing, stir fusion and insulation under 55 ℃ of conditions, slowly add micropowder silica gel 10g while stirring, micropowder silica gel is uniformly dispersed, it is standby to get compositions;
(2) make microemulsion with propoxylation methyl glucoside 15g, isobutanol 5ml, ethyl acetate 40ml, in emulsion, add cefprozil 210g, place 40 ℃ of water-baths;
(3) add resulting composition in (1) in microemulsion, be stirred to evenly, as reactant liquor, the pH value of regulating this reactant liquor with 10% NaOH solution is 8.0, adds an amount of methanol with this solution, isothermal reaction 1 hour;
(4) reactant liquor is cooled to 0 ℃, the glutaraldehyde that adds 0.08 times of reactant liquor volume continues to stir 30 minutes, slowly is warming up to 40 ℃ again, and adding glacial acetic acid to pH value is 2.0, obtains suspension;
(5) treat that sedimentation is complete after static, the supernatant that inclines filters, and washes with water to no aldehyde and distinguishes the flavor of, and drains, promptly.
The preparation of the solid preparation of embodiment 2 cefprozils
(1) with after xanthan gum 45g, the fibroin albumen 10g mixing, stir fusion and insulation under 60 ℃ of conditions, slowly add micropowder silica gel 10g while stirring, micropowder silica gel is uniformly dispersed, it is standby to get compositions;
(2) make microemulsion with propoxylation methyl glucoside 120g, isobutanol 40ml, ethyl acetate 320ml, in emulsion, add cefprozil 715g, place 60 ℃ of water-baths;
(3) compositions of the middle gained of adding (1) in microemulsion is stirred to evenly, and as reactant liquor, the pH value of regulating this reactant liquor with 10% NaOH solution is 10.0, adds an amount of methanol with this solution, isothermal reaction 2 hours;
(4) reactant liquor is cooled to 0 ℃, the glutaraldehyde that adds 0.125 times of reactant liquor volume continues to stir 30 minutes, slowly is warming up to 60 ℃ again, and adding glacial acetic acid to pH value is 4.0, obtains suspension;
(5) treat that sedimentation is complete after static, the supernatant that inclines filters, and washes with water to no aldehyde and distinguishes the flavor of, and drains, promptly.
The preparation of the solid preparation of embodiment 3 cefprozils
(1) with after xanthan gum 25g, the fibroin albumen 10g mixing, stir fusion and insulation under 58 ℃ of conditions, slowly add micropowder silica gel 10g while stirring, micropowder silica gel is uniformly dispersed, it is standby to get compositions;
(2) make microemulsion with propoxylation methyl glucoside 60g, isobutanol 20ml, ethyl acetate 160ml and in emulsion, add cefprozil 315g, place 50 ℃ of water-baths;
(3) add resulting composition in (1) in microemulsion, be stirred to evenly, as reactant liquor, the pH value of regulating this reactant liquor with 10% NaOH solution is 9.0, adds an amount of methanol with this solution, isothermal reaction 1.5 hours;
(4) reactant liquor is cooled to 0 ℃, the glutaraldehyde that adds 0.1 times of reactant liquor volume continues to stir 30 minutes, slowly is warming up to 50 ℃ again, and adding glacial acetic acid to pH value is 3.0, obtains suspension;
(5) treat that sedimentation is complete after static, the supernatant that inclines filters, and washes with water to no aldehyde and distinguishes the flavor of, and drains, promptly.
The cefprozil nano-microcapsule of gained among above-mentioned 1～3 embodiment is made granule, dry suspension or tabletting by dry method or wet granulation and pharmaceutic adjuvant mix homogeneously such as diluent, disintegrating agent, adhesive, lubricant and fluidizer or incapsulate.
The preparation of the dried mixed suspension preparation of embodiment 4 cefprozils
(1) with after xanthan gum 35g, the fibroin albumen 10g mixing, stir fusion and insulation under 56 ℃ of conditions, slowly add micropowder silica gel 10g while stirring, micropowder silica gel is uniformly dispersed, it is standby to get compositions;
(2) make microemulsion with propoxylation methyl glucoside 90g, isobutanol 30ml, ethyl acetate 240ml, in emulsion, add cefprozil 495g, place 60 ℃ of water-baths;
(3) add resulting composition in (1) in microemulsion, be stirred to evenly, as reactant liquor, the pH value of regulating this reactant liquor with 10% NaOH solution is 10.0, adds an amount of methanol with this solution, isothermal reaction 2 hours;
(4) reactant liquor is cooled to 0 ℃, the glutaraldehyde that adds 0.125 times of reactant liquor volume continues to stir 30 minutes, slowly is warming up to 60 ℃ again, and adding glacial acetic acid to pH value is 4.0, obtains suspension;
(5) treat that sedimentation is complete after static, the supernatant that inclines filters, and washes with water to no aldehyde and distinguishes the flavor of, and drains, and is standby;
(6) sodium carbonate is crossed 80 mesh sieves, got (d) gained precipitum, 4g microcrystalline Cellulose, 1g sodium carbonate, put into high speed granulator, do and mixed 1 minute, add 11g 20% arabic gum aqueous solution, stirred discharging 5 minutes, 18 order nylon mesh are granulated, airpillow-dry, 65 ℃ of inlet temperature, 38.5 ℃ of drop temperatures, pellet moisture is 3.68%, 16 order iron wire sieve granulate; Granule is crossed 40 mesh sieves sieve fine powder, get coarse granule;
(7) Icing Sugar is crossed 100 mesh sieves, taken by weighing the 0.05g lemon yellow and add in the 1.5g1%HPMC solution and stir, take by weighing 20g Icing Sugar, 8g mannitol, the sweet high speed granulator of putting into of 0.5g A Siba, do and mixed 1 minute, pour the 1%HPMC solution that adds lemon yellow into stir about 5 minutes, 150 rev/mins of mixing speeds, 18 order nylon mesh are granulated, airpillow-dry, 65 ℃ of inlet temperature, drop temperature is controlled at 30 ℃-40 ℃, 16 order iron wire sieve granulate, discharging;
(8) measure medicine-containing particle content, the mixed of pressing 2:1 with sugared granule is even, is up to the standards, and packing specification is 1.5g/ bag (in a cefprozil), promptly.
The preparation of embodiment 5 cefprozil tablets, external stripping and clinical research untoward reaction situation
One, the preparation of cefprozil tablet
(1) with after xanthan gum 26g, the fibroin albumen 10g mixing, stir fusion and insulation under 57 ℃ of conditions, slowly add micropowder silica gel 10g while stirring, micropowder silica gel is uniformly dispersed, it is standby to get compositions;
(2) make microemulsion with propoxylation methyl glucoside 30g, isobutanol 10ml, ethyl acetate 80ml, in emulsion, add cefprozil 414g, place 50 ℃ of water-baths;
(3) add resulting composition in (1) in microemulsion, be stirred to evenly, as reactant liquor, the pH value of regulating this reactant liquor with 10% NaOH solution is 9.0, adds an amount of methanol with this solution, isothermal reaction 1.5 hours;
(4) reactant liquor is cooled to 0 ℃, the glutaraldehyde that adds 0.1 times of reactant liquor volume continues to stir 30 minutes, slowly is warming up to 50 ℃ again, and adding glacial acetic acid to pH value is 3.0, obtains suspension;
(5) treat that sedimentation is complete after static, the supernatant that inclines filters, and washes with water to no aldehyde and distinguishes the flavor of, and drains, and is standby.
(6) get gained precipitum cefprozil meter 300g and hydrogenated vegetable oil 35g, carboxymethyl starch sodium 22g and micropowder silica gel 5g in the step (4), tabletting gets the tablet that the cefprozil specification is the 50mg/ sheet.
Two, the external stripping of cefprozil tablet
Dissolution medium is that 100r/min, temperature are 37.0 ℃ ± 0.5 ℃ for pH6.80 phosphate buffer 900 ml, the rotating speed of handling through the degassing, respectively at sampling 5 ml behind 5,15,30,45,60,120,240,360 and 480 min, with little lonely L membrane filtration, and benefit man equivalent medium, get filtrate and measure it, find c (m1), calculate accumulation stripping percentage rate by the standard curve regression equation at wavelength 321 nm places, and with commercially available cefprozil tablet in contrast, see Table 1.
The result shows, compares with the cefprozil ordinary tablet, and cefprozil tablet of the present invention has tangible slow releasing function, has reduced toxic and side effects, has improved patient's compliance.
Three, cefprozil tablet clinical research untoward reaction situation of the present invention
100 routine patients, wherein there are 18 examples to suffer from enteritis, participated in the clinical research of this product, be equally divided into test group and matched group at random, wherein test group is taken cefprozil tablet of the present invention, matched group is taken commercially available cefprozil conventional tablet, specification is the 50mg/ sheet, takes twice every day, each a slice, took continuously 12 days, and saw Table 2.
Because preparation of the present invention has tangible slow releasing function, having avoided medicine to dash forward releases, and then reduced toxic and side effects, improved patient's compliance, compared, avoided gastrointestinal reaction, anaphylaxis with commercially available common cefprozil preparation, the generation of untoward reaction such as liver and gall, central nervous system, blood system, kidney, and to enteritis patient's not influence of intestinal microbial population normal condition, avoided superinfection, therefore had significant technological progress.
Obviously, the foregoing description only is the example of enumerating for clearly demonstrating among the present invention, and is not to be qualification to protection domain of the present invention.The variation of other form of making on the basis of the above still is among protection scope of the present invention.
Claims (6)
1. cefprozil solid preparation, it is characterized in that, contain cefprozil nano-microcapsule and pharmaceutic adjuvant in the preparation, described cefprozil nano-microcapsule is that 6～11:1 makes by cefprozil and carrier material with ratio of weight and number, described carrier material is xanthan gum-fibroin albumen-micropowder silica gel compositions, and wherein the ratio of weight and number of xanthan gum, fibroin albumen and micropowder silica gel is 1.5～4.5:1.
2. solid preparation according to claim 1 is characterized in that, the ratio of weight and number of described xanthan gum, fibroin albumen and micropowder silica gel is 2.6:1.
3. solid preparation according to claim 2 is characterized in that, described pharmaceutic adjuvant is diluent, disintegrating agent, adhesive, lubricant and fluidizer.
4. solid preparation according to claim 3 is characterized in that, the dosage form of described preparation is tablet, capsule, dry suspension or granule.
5. a preparation method for preparing as claim 1,2,3 or 4 described solid preparations is characterized in that it comprises the steps:
A, after ratio is mixed by weight with fibroin albumen with xanthan gum, under 55～60 ℃ of conditions, stir fusion and insulation, slowly add micropowder silica gel while stirring, micropowder silica gel is uniformly dispersed, compositions is standby;
B, be that the ratio of 3:1:8 makes microemulsion, in emulsion, add cefprozil, place 40～60 ℃ of water-baths according to propoxylation methyl glucoside weight, isobutanol volume, ethyl acetate volume ratio;
C, add step a resulting composition in microemulsion, be stirred to evenly, as reactant liquor, the pH value of regulating this reactant liquor with the NaOH solution of mass concentration 10% is 8.0～10.0, adds an amount of methanol with this solution, isothermal reaction 1～2 hour;
D, reactant liquor is cooled to 0 ℃, the glutaraldehyde that adds 0.08～0.125 times of reactant liquor volume continues to stir 30 minutes, slowly is warming up to 40～60 ℃ again, and adding glacial acetic acid to the value of pH is 2.0～4.0, obtains suspension;
E, treat that sedimentation is complete after static, the supernatant that inclines filters, and washes with water to no aldehyde to distinguish the flavor of, and drains, promptly.
6. the preparation method of solid preparation according to claim 5 is characterized in that:
The temperature that stirs fusion and insulation among the described step a is 57 ℃;
Bath temperature is 50 ℃ among the described step b;
The pH value of reactant liquor is 9.0 among the described step c; Isothermal reaction 1.5 hours;
The glutaraldehyde consumption is 0.1 times of reactant liquor volume in the described steps d, slowly is warming up to 50 ℃, and the glacial acetic acid adjust pH is 3.0.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201010518154A CN101953780B (en) | 2010-10-25 | 2010-10-25 | Cefprozil solid preparation and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201010518154A CN101953780B (en) | 2010-10-25 | 2010-10-25 | Cefprozil solid preparation and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101953780A true CN101953780A (en) | 2011-01-26 |
| CN101953780B CN101953780B (en) | 2012-09-05 |
Family
ID=43481540
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201010518154A Active CN101953780B (en) | 2010-10-25 | 2010-10-25 | Cefprozil solid preparation and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101953780B (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100028451A1 (en) * | 2006-09-26 | 2010-02-04 | Trustees Of Tufts College | Silk microspheres for encapsulation and controlled release |
| CN101700232A (en) * | 2009-11-23 | 2010-05-05 | 陶灵刚 | Cefprozil submicron emulsion solid preparation and new application thereof |
-
2010
- 2010-10-25 CN CN201010518154A patent/CN101953780B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100028451A1 (en) * | 2006-09-26 | 2010-02-04 | Trustees Of Tufts College | Silk microspheres for encapsulation and controlled release |
| CN101700232A (en) * | 2009-11-23 | 2010-05-05 | 陶灵刚 | Cefprozil submicron emulsion solid preparation and new application thereof |
Non-Patent Citations (2)
| Title |
|---|
| 《东华大学学报》 20031031 张幼珠 等 再生丝素蛋白－壳聚糖包药微囊的质量研究 第117页 1-6 第29卷, 第5期 2 * |
| 《国外医药抗生素分册》 19980930 唐建国 口服头孢菌素-头孢丙烯 全文 1-6 第19卷, 第5期 2 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101953780B (en) | 2012-09-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO761981L (en) | ||
| CN101816635B (en) | Cephalosporin suspension granule and preparation method thereof | |
| CN101780085B (en) | Cefprozil medicinal composition | |
| CN101757042A (en) | Probiotic pellet preparation and preparing method thereof | |
| CN102875573B (en) | Cefixime compound and pharmaceutical composition thereof | |
| CN106176646B (en) | Tosufloxacin tosylate dispersible tablets and preparation method thereof | |
| CN102614174A (en) | Dry suspension containing amoxicillin and potassium clavulanate | |
| CN101953780B (en) | Cefprozil solid preparation and preparation method thereof | |
| CN101940575B (en) | Cefditoren pivoxil solid preparation and preparation method thereof | |
| CN103145733B (en) | Amoxicillin compound and pharmaceutical composition of amoxicillin compound and potassium clavulanate | |
| CN102643255A (en) | Andrographolide compound | |
| CA2330390C (en) | Sugar coated tablets | |
| KR20040030955A (en) | Bile acid absorbent/adsorbent | |
| US5733551A (en) | Process for preparing spheroids of plant origin | |
| CN104739792A (en) | Method for preparing roxithromycin dispersible tablet | |
| CN101966156B (en) | Azithromycin for suspension and preparation method thereof | |
| WO2004047550A1 (en) | Granular composition and process for producing the same | |
| CN101732315A (en) | Method for preparing enrofloxacin microcapsules | |
| CN102335133B (en) | Cefaclor lipidosome solid preparation | |
| CN112007010A (en) | Stable cefuroxime axetil pharmaceutical preparation composition and preparation method thereof | |
| CN102000338B (en) | Silicon dioxide pellet and preparation method thereof | |
| CN85101689A (en) | Nifedipine preparation and preparation method thereof | |
| CN110893232A (en) | Cefoperazone sodium and sulbactam sodium powder injection for injection and preparation method thereof | |
| CN101138552A (en) | Preparation method of almecillin V potassium granular formulation | |
| CN101897702B (en) | Amoxicillin sulbactam pivoxil capsule and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |